Compare ImmunityBio Inc. Common Stock (IBRX) vs Kimberly Clark Corp (KMB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ImmunityBio Inc. Common Stock vs Kimberly Clark Corp — how do they compare? ImmunityBio Inc. Common Stock trades at $10 (market cap $10.33B), while Kimberly Clark Corp trades at $97.57 (market cap $32.09B). The key difference: Kimberly Clark Corp is far larger — about 3.1× ImmunityBio Inc. Common Stock's market cap, and Kimberly Clark Corp pays a 5.31% dividend while ImmunityBio Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold ImmunityBio Inc. Common Stock for 0 Days and Kimberly Clark Corp for 93 Days on average.
| IBRX | KMB | |
|---|---|---|
Market Cap | $10.33B | $32.09B |
Volume | 11,745,198 | 2,800,459 |
Sector | Health | Consumer Staples |
52-Week High | $11.55 | $121.44 |
52-Week Low | $1.98 | $93.05 |
Typical Hold Time | 0 Days | 93 Days |
Enterprise Value | $10.79B | $37.65B |
Dividend Yield | — | 5.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Kimberly-Clark (KMB) trades at $97.74, up 1.0% on the day, with a bearish technical signal but strong dividend yield of 5.16%. Recent earnings show a mix of beats and a Q2 2026 miss, while the pending Kenvue acquisition and executive transitions dominate news. The stock is undervalued relative to its consensus price target of $117.25, with a P/E of 19.07 and robust profitability metrics including a net income margin of 11.79%.
KMB offers a high dividend yield and valuation upside, but risks include integration challenges from the Kenvue deal, cash flow pressures, and bearish technical trends. Analyst consensus is cautious with 61% hold ratings, reflecting concerns over execution and sustainability of the dividend amid acquisition-related liabilities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ImmunityBio Inc. Common Stock
ImmunityBio develops immune-based therapies for cancer and infectious diseases. Its programs are designed to activate and strengthen the body’s immune response.
Read more on IBRX →About Kimberly Clark Corp
With around half of sales from personal care and another third from tissue products, Kimberly-Clark sits as a leading manufacturer of tissue and hygiene realm. Its brand mix includes Huggies, Pull-Ups, Kotex, Depend, Kleenex, and Cottonelle. The firm also operates K-C Professional, which partners with businesses to provide safety and sanitary products for the workplace. Kimberly-Clark generates just over of half its sales in North America and more than 10% in Europe, with the rest primarily concentrated in Asia and Latin America.
Read more on KMB →
